Current status and future prospects for a vaccine against American trypanosomiasis

Vandanajay Bhatia, Nisha Garg

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The clinically relevant pathognomonic consequences of human infection by Trypanosoma cruzi are dilation and hypertrophy of the left ventricle walls and thinning of the apex. The major complications and debilitating evolutionary outcomes of chronic infection include ventricular fibrillation, thromboembolism and congestive heart failure. American trypanosomiasis (Chagas disease) poses serious public healthcare and budgetary concerns. The currently available drugs, although effective against acute infection, are highly toxic and ineffective in arresting or attenuating clinical disease symptoms in chronic patients. The development of an efficacious prophylactic vaccine faces many challenges, and progress is slow, despite several years of effort. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested in animal models, and some efforts have been successful in controlling infection and disease. This review will summarize the accumulated knowledge about the parasite and disease, as well as pathogenesis and protective immunity. The authors will discuss the efforts to date, and the challenges faced in achieving an efficient prophylactic vaccine against human American trypanosomiasis, and present the future perspectives.

Original languageEnglish (US)
Pages (from-to)867-880
Number of pages14
JournalExpert Review of Vaccines
Volume4
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Chagas Disease
Vaccines
Infection
Immunity
Animal Models
Antigens
Poisons
Trypanosoma cruzi
Thromboembolism
Ventricular Fibrillation
Hypertrophy
Heart Ventricles
Disease Progression
Dilatation
Parasites
Heart Failure
Pathology
Delivery of Health Care
Pharmaceutical Preparations

Keywords

  • American trypanosomiasis
  • Chagas disease
  • Immunity
  • Pathogenesis
  • Trypanosoma cruzi
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Current status and future prospects for a vaccine against American trypanosomiasis. / Bhatia, Vandanajay; Garg, Nisha.

In: Expert Review of Vaccines, Vol. 4, No. 6, 12.2005, p. 867-880.

Research output: Contribution to journalArticle

@article{569148e0c8714de28186866e0945975a,
title = "Current status and future prospects for a vaccine against American trypanosomiasis",
abstract = "The clinically relevant pathognomonic consequences of human infection by Trypanosoma cruzi are dilation and hypertrophy of the left ventricle walls and thinning of the apex. The major complications and debilitating evolutionary outcomes of chronic infection include ventricular fibrillation, thromboembolism and congestive heart failure. American trypanosomiasis (Chagas disease) poses serious public healthcare and budgetary concerns. The currently available drugs, although effective against acute infection, are highly toxic and ineffective in arresting or attenuating clinical disease symptoms in chronic patients. The development of an efficacious prophylactic vaccine faces many challenges, and progress is slow, despite several years of effort. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested in animal models, and some efforts have been successful in controlling infection and disease. This review will summarize the accumulated knowledge about the parasite and disease, as well as pathogenesis and protective immunity. The authors will discuss the efforts to date, and the challenges faced in achieving an efficient prophylactic vaccine against human American trypanosomiasis, and present the future perspectives.",
keywords = "American trypanosomiasis, Chagas disease, Immunity, Pathogenesis, Trypanosoma cruzi, Vaccines",
author = "Vandanajay Bhatia and Nisha Garg",
year = "2005",
month = "12",
doi = "10.1586/14760584.4.6.867",
language = "English (US)",
volume = "4",
pages = "867--880",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Current status and future prospects for a vaccine against American trypanosomiasis

AU - Bhatia, Vandanajay

AU - Garg, Nisha

PY - 2005/12

Y1 - 2005/12

N2 - The clinically relevant pathognomonic consequences of human infection by Trypanosoma cruzi are dilation and hypertrophy of the left ventricle walls and thinning of the apex. The major complications and debilitating evolutionary outcomes of chronic infection include ventricular fibrillation, thromboembolism and congestive heart failure. American trypanosomiasis (Chagas disease) poses serious public healthcare and budgetary concerns. The currently available drugs, although effective against acute infection, are highly toxic and ineffective in arresting or attenuating clinical disease symptoms in chronic patients. The development of an efficacious prophylactic vaccine faces many challenges, and progress is slow, despite several years of effort. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested in animal models, and some efforts have been successful in controlling infection and disease. This review will summarize the accumulated knowledge about the parasite and disease, as well as pathogenesis and protective immunity. The authors will discuss the efforts to date, and the challenges faced in achieving an efficient prophylactic vaccine against human American trypanosomiasis, and present the future perspectives.

AB - The clinically relevant pathognomonic consequences of human infection by Trypanosoma cruzi are dilation and hypertrophy of the left ventricle walls and thinning of the apex. The major complications and debilitating evolutionary outcomes of chronic infection include ventricular fibrillation, thromboembolism and congestive heart failure. American trypanosomiasis (Chagas disease) poses serious public healthcare and budgetary concerns. The currently available drugs, although effective against acute infection, are highly toxic and ineffective in arresting or attenuating clinical disease symptoms in chronic patients. The development of an efficacious prophylactic vaccine faces many challenges, and progress is slow, despite several years of effort. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested in animal models, and some efforts have been successful in controlling infection and disease. This review will summarize the accumulated knowledge about the parasite and disease, as well as pathogenesis and protective immunity. The authors will discuss the efforts to date, and the challenges faced in achieving an efficient prophylactic vaccine against human American trypanosomiasis, and present the future perspectives.

KW - American trypanosomiasis

KW - Chagas disease

KW - Immunity

KW - Pathogenesis

KW - Trypanosoma cruzi

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=29944436176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944436176&partnerID=8YFLogxK

U2 - 10.1586/14760584.4.6.867

DO - 10.1586/14760584.4.6.867

M3 - Article

VL - 4

SP - 867

EP - 880

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -